Zobrazeno 1 - 10
of 327
pro vyhledávání: ''
Autor:
Anne-Gaëlle Dosne, Elodie Valade, Nele Goeyvaerts, Peter De Porre, Anjali Avadhani, Anne O’Hagan, Lilian Y. Li, Daniele Ouellet, Juan Jose Perez Ruixo
Publikováno v:
Cancer Chemotherapy and Pharmacology. 89:151-164
Background Exposure–response analyses were conducted to explore the relationship between selected efficacy and safety endpoints and serum phosphate (PO4) concentrations, a potential biomarker of efficacy and safety, in locally advanced or metastati
Autor:
Cindy L. O'Bryant, Stefan Zajic, Reginald Ewesuedo, Ashley Milton, Mehmet Akce, Zhi-Yi Zhang, Yongqiang Tang, Peng Pan, Sarina Anne Piha-Paul, Divya Gupta, Anthony B. El-Khoueiry, Patricia L. Judson, Emeline Bacque
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose The purpose of this study is to characterize niraparib pharmacokinetics (PK) and safety in patients with normal hepatic function (NHF) versus moderate hepatic impairment (MHI). Methods Patients with advanced solid tumors were stratified by NH
Publikováno v:
Cancer Chemotherapy and Pharmacology. 88:533-542
Genetic variation in the activation of the prodrug cyclophosphamide (CP) by cytochrome P450 (CYP) enzymes has been shown to influence outcomes. However, CYP are also subject to phenoconversion due to either the effects of comedications or cancer asso
Autor:
Malaz Abutarif, David Jaworowicz, Alexander E. Perl, Jill Fiedler-Kelly, Youngsook Choi, Nigel H. Russell, Siddhartha Ganguly, Alwin Krämer, Ophelia Yin, Mark J. Levis, Samer K. Khaled, Dongwoo Kang, Giovanni Martinelli, Jorge E. Cortes, Elizabeth Ludwig, Hannah Huang
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose This analysis evaluated the relationship between concentrations of quizartinib and its active metabolite AC886 and QT interval corrected using Fridericia’s formula (QTcF) in patients with relapsed/refractory acute myeloid leukemia (AML) tre
Autor:
Carlos Becerra, Donald A. Richards, Thomas E. Boyd, Paul Conkling, Hillary H. Wu, Tracy Murray Stewart, Joe Stephenson, Daniel D. Von Hoff, Nicholas J. Vogelzang, Robert A. Casero, Lawrence Garbo, David Smith, Michael L. Fitzgerald, Robert M. Jotte, Laurence J. Marton
Publikováno v:
Cancer Chemother Pharmacol
PURPOSE: Polyamines are absolutely essential for maintaining tumor cell proliferation. PG-11047, a polyamine analogue, is a nonfunctional competitor of the natural polyamine spermine that has demonstrated anticancer activity in cells and animal model
Autor:
Rama Suresh, Saiama N. Waqar, Haeseong Park, Benjamin R. Tan, Nikolaos A. Trikalinos, Sarah Larson, Kerry J. Williams, Daniel Morgensztern, A. Craig Lockhart, Andrea Wang-Gillam, Jingqin Luo, Ramaswamy Govindan, Brian A. Van Tine
Publikováno v:
Cancer Chemother Pharmacol
PURPOSE: Resistance to treatment with inhibitors of mammalian target of rapamycin (mTOR) is partially mediated by activation of epidermal growth factor receptor (EGFR). We conducted a phase I study to determine the recommended phase II dose (RP2D) an
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Berzosertib (formerly M6620) is the first-in-class inhibitor of ataxia–telangiectasia and Rad3-related protein, a key component of the DNA damage response, and being developed in combination with chemotherapy for the treatment of patients w
Autor:
Takahiro Ebata, Yutaka Fujiwara, Shunsuke Kondo, P. Rietschel, Noboru Yamamoto, Tasha N. Sims, Toshio Shimizu, Akihiko Shimomura, Siyu Li, Anne Paccaly, Takafumi Koyama, Satoru Iwasa, Shigehisa Kitano
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Part 1 of this two-part, open-label, Phase 1 study (NCT03233139) assessed the safety, tolerability, pharmacokinetics, immunogenicity, and clinical activity of cemiplimab in Japanese patients with advanced malignancies. Methods Patients receiv
Autor:
Elisabeth Odin, Göran Carlsson, Helena Taflin, Roger Tell, Bengt Gustavsson, Yvonne Wettergren
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose The aim was to explore the correlation between increasing doses of [6R]-5,10-methylenetetrahydrofolate (arfolitixorin) and plasma concentrations of deoxyuridine (dUr) in patients with metastatic colorectal cancer (mCRC), subjected to 5-fluoro
Autor:
Yuying Gao, Lucy Liu, Lyndah Dreiling, Helen Collins, Amy W. Hsu, Ago Ahene, Monica Macal, Hong Xiang
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose To report population pharmacokinetic (PK) analysis of the phase 1 study (FPA144-001, NCT02318329) and to select a clinical dose and schedule that will achieve an empirical target trough concentration (Ctrough) for an anti-fibroblast growth fa